Autopsy report · NCT03579888

CD19-Specific T Cells Post AlloSCT

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study halted prematurely”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 years before it started.
Ran for about 11 months before it stopped.
4 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: M.D. Anderson Cancer Center
Sponsor type: University, hospital or other
Conditions: B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Mantle Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma
Interventions: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells; Cyclophosphamide; Fludarabine
Participants: 4
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.